<DOC>
	<DOCNO>NCT00730639</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness MDX-1106 patient certain type cancer . Another purpose determine MDX-1106 absorbed distribute within body , 's eventually eliminate .</brief_summary>
	<brief_title>A Phase 1 Study Nivolumab ( BMS-936558 ) Subjects With Advanced Recurrent Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects must mCRPC , RCC , MEL , Nonsmallcell lung cancer ( NSCLC ) , Colorectal Cancer ( CRC ) , advance ( nonresectable ) , recurrent alternative , curative standard exist Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Must least 1 measurable lesion Subjects mCRPC nonmeasurable bone lesion must either progression new lesion Prostatespecific antigen ( PSA ) progression within 6week period study administration At least 1 5 prior systemic therapy advanced/recurrent disease Prior treat brain meningeal metastasis must without Magnetic resonance imaging ( MRI ) evidence progression least 8 week immunosuppressive dos systemic steroid least 2 week study drug administration Prior systemic radiation therapy must complete least 4 week study drug administration . Prior focal radiotherapy complete least 2 week prior study drug administration Immunosuppressive dose systemic medication , steroid absorb topical steroid must discontinue least 2 week study drug administration Prior surgery require general anesthesia must complete least 2 week study drug administration . Surgery require local/epidural anesthesia must complete least 72 hour study drug administration History severe hypersensitivity reaction Monoclonal antibody ( mAb ) Subjects active autoimmune disease document history autoimmune disease , history syndrome require systemic steroid immunosuppressive medication , except subject vitiligo resolve childhood asthma/atopy Prior therapy antiProgrammed death1 ( PD1 ) , antiPDL1 , antiPDL2 , anti Cytotoxic tlymphocyte antigen4 ( CTLA4 ) antibody ( antibody target T cell costimulation pathway ) Known history Human Immunodeficiency Virus Active infection require therapy , positive test Hepatitis B surface antigen Hepatitis C ribonucleic acid ( RNA ) Underlying medical condition make administration study drug hazardous Concurrent medical condition require use immunosuppressive medication , immunosuppressive dos systemic absorbable topical corticosteroid Use investigational drug ( drug market indication ) within 28 day least 5 halflives ( whichever longer ) study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>